Novo Nordisk and Eli Lilly: The Competitive Race in the GLP-1 Market Unveiled
As the race in the GLP-1 market intensifies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stand at distinct crossroads in their growth trajectories. Eli Lilly currently leads the market, enjoying a larger share and the potential for extended exclusivity for its products. This scenario raises significant questions about Novo Nordisk’s competitive strategies as...








